133 related articles for article (PubMed ID: 2481657)
1. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy.
Siegel JA; Lee RE; Pawlyk DA; Horowitz JA; Sharkey RM; Goldenberg DM
Int J Rad Appl Instrum B; 1989; 16(6):553-9. PubMed ID: 2481657
[TBL] [Abstract][Full Text] [Related]
2. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
Siegel JA; Pawlyk DA; Lee RE; Sasso NL; Horowitz JA; Sharkey RM; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):1039s-1042s. PubMed ID: 2297717
[TBL] [Abstract][Full Text] [Related]
3. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
Juweid M; Sharkey RM; Siegel JA; Behr T; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5827s-5831s. PubMed ID: 7493354
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
5. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy.
Macey DJ; DeNardo SJ; DeNardo GL; DeNardo DA; Shen S
Clin Nucl Med; 1995 Feb; 20(2):117-25. PubMed ID: 7720301
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
Acta Oncol; 2005; 44(6):579-88. PubMed ID: 16165917
[TBL] [Abstract][Full Text] [Related]
9. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
Behr TM; Béhé M; Sgouros G
Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
[TBL] [Abstract][Full Text] [Related]
10. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
11. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
[TBL] [Abstract][Full Text] [Related]
12. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
13. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
14. Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
Cancer; 2002 Feb; 94(4 Suppl):1235-9. PubMed ID: 11877751
[TBL] [Abstract][Full Text] [Related]
15. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
16. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
[TBL] [Abstract][Full Text] [Related]
17. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Hanley D; Herskovic T; Markowitz A; Siegel J; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
Sharkey RM; Juweid M; Shevitz J; Behr T; Dunn R; Swayne LC; Wong GY; Blumenthal RD; Griffiths GL; Siegel JA
Cancer Res; 1995 Dec; 55(23 Suppl):5935s-5945s. PubMed ID: 7493374
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
Juweid M; Sharkey RM; Behr T; Swayne LC; Herskovic T; Pereira M; Rubin AD; Hanley D; Dunn R; Siegel J; Goldenberg DM
J Nucl Med; 1996 Jun; 37(6):905-11. PubMed ID: 8683309
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]